Why we don't show a single “fair value” for ALAB
A trailing-FCF DCF can't fairly anchor Astera Labs, Inc. Common Stock right now — free cash flow has been negative in recent years. For a company in this position, trailing free cash flow understates what the business actually earns for owners, so any “fair value” built on it would be misleadingly low. Off today's cash-flow base, no plausible growth rate bridges to the current price — the market is valuing normalized future cash flows, not the depressed base. The model scenarios below are shown for reference only.
| Scenario | FCF growth (fading to 2.5%) | Discount | Value / share |
|---|---|---|---|
| Conservative | 15.0%/yr | 12.5% | $5.17 |
| Base case | 18.0%/yr | 11.5% | $6.24 |
| Optimistic | 20.0%/yr | 10.5% | $7.44 |
Current Price
$247.11
Market-Implied Growth
N/A
Base-Case Model Value
$6.24
model output — not a price target
Edit the assumptions to see how they change the estimated fair value. Opens seeded with TGM's data-driven base case for ALAB (growth from its own 5-year record, discount from its beta), so the sandbox starts where the scenarios above leave off. Illustrative model — not investment advice.
Base inputs: FCF $43.5M · 0.17B shares · net cash $167.6M
Estimated Fair Value
$6.24
-97.5% vs $247.11
How the estimated fair value shifts with the discount rate (WACC) and terminal growth, holding your 18.0%/yr FCF growth and 10-year horizon fixed. Green = above today's $247.11; red = below. Your current case is outlined.
| WACC ↓ / Terminal → | 1.50% | 2.00% | 2.50% | 3.00% | 3.50% |
|---|---|---|---|---|---|
| 9.5% | $7.17 | $7.51 | $7.90 | $8.35 | $8.87 |
| 10.5% | $6.41 | $6.67 | $6.96 | $7.29 | $7.67 |
| 11.5% | $5.81 | $6.02 | $6.24 | $6.49 | $6.77 |
| 12.5% | $5.33 | $5.49 | $5.66 | $5.86 | $6.07 |
| 13.5% | $4.92 | $5.05 | $5.19 | $5.35 | $5.52 |
